Filing Flows › X4 Pharmaceuticals (XFOR) › Q2 2025
X4 Pharmaceuticals (XFOR) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 8, 2025
X4 Pharmaceuticals (XFOR) reported revenue of $1.7M for the second quarter 2025 (Q2 2025), +202% from a year earlier and +89% from the quarter before.
X4 Pharmaceuticals, Q2 2025: revenue $1.7M (+202% year over year), net loss $25.7M, operating cash flow −$29.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7M | +89% | +202% |
| Operating profit | −$26.2M | — | — |
| Net earnings | −$25.7M | -9228% | — |
| Operating cash flow | −$29.9M | — | — |
What changed
Revenue was $1.7M in Q2 2025, up 202% year over year and up 89% from the previous quarter.
Operating costs exceeded revenue by $26.2M, an operating margin of -1543.1%. The quarter ended with a net loss of $25.7M, after a profit of $282K the previous quarter.
Operating cash flow was −$29.9M. Non-cash charges added back $355K of depreciation and amortization and $748K of share-based compensation. Working capital and other items used $5.3M.
Questions
What was X4 Pharmaceuticals' revenue in the second quarter 2025?
X4 Pharmaceuticals (XFOR) reported revenue of $1.7M for the second quarter 2025 (Q2 2025), +202% from a year earlier and +89% from the quarter before.
Source: X4 Pharmaceuticals 10-Q on SEC EDGAR.